CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 6: 441 - 441-446

DOI: https://doi.org/10.2095-3593.2026.010002

Correlation Analysis of Echocardiographic Parameters， Serum Adropin Levels，and Treatment Outcomes in Patients with Dilated Cardiomyopathy

Expand
  • 1.Department of Ultrasound Diagnosis， Xinyang People′s Hospital， Henan Xinyang 464000， China；
    2.Department of Ultrasound Diagnosis， the Seventh People′s Hospital of Zhengzhou City， Henan Zhengzhou 450000， China

Received date: 2025-03-20

  Revised date: 2025-03-27

  Accepted date: 2026-01-07

  Online published: 2026-01-07

Fold

Abstract

Objective： To investigate the changes in echocardiographic parameters and serum Adropin levels in patients with dilated cardiomyopathy (DCM) before and after treatment， and analyze their correlation with treatment efficacy and their evaluation value. Methods： A total of 96 patients with DCM who were treated in our hospital from May 2022 to May 2024 were selected retrospectively. All patients were given conventional treatment， and they were divided into an effective group of 70 patients and an ineffective group of 26 patients based on the therapeutic effect after 3 months of treatment. The clinical data and echocardiographic parameters [left ventricular end-systolic volume (LVESV)， left ventricular end-diastolic volume (LVEDV)， left atrial diameter (LAD)]， serum Adropin levels were compared between the two groups. The impact of echocardiographic parameters and serum Adropin levels on the therapeutic effect was analyzed， and their correlation with the therapeutic effect was analyzed. The evaluation value of echocardiographic parameters and serum Adropin on the therapeutic effect was analyzed. Results： After treatment， the LVESV， LVEDV， LAD， and serum Adropin levels in the effective group were lower than those before treatment and lower than those in the ineffective group (P<0.05)； multivariate Logistic regression analysis showed that after adjusting for age， disease duration， and NYHA functional classification， LVESV， LVEDV， LAD， and Adropin were still associated with treatment efficacy (P<0.05). Partial correlation analysis showed that LVESV， LVEDV， LAD， and Adropin were negatively correlated with treatment efficacy (P<0.05).After one month of treatment， the AUC values for the individual and combined assessment of LVESV， LVEDV， LAD， serum Adropin， and the therapeutic effect were 0.769， 0.757， 0.790， 0.754， and 0.916， respectively. The AUC value for the combined assessment was greater than that for each individual indicator (P<0.05). Conclusion： LVESV， LVEDV， LAD， and serum Adropin levels are factors associated with the therapeutic efficacy in patients with DCM， and are negatively correlated with the therapeutic efficacy. Combined detection of their levels has certain evaluation value for the therapeutic efficacy.

Key words： ; font-size:medium; ">Dilated cardiomyopathy； Echocardiographic parameters； Energy balance-related proteins； Correlation analysis； Evaluation value

Cite this article

JIN Fengyang, YANG Fan, LIU Yuanjun, ZHAI Tingting . Correlation Analysis of Echocardiographic Parameters， Serum Adropin Levels，and Treatment Outcomes in Patients with Dilated Cardiomyopathy[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(6) : 441 -441-446 . DOI: 10.2095-3593.2026.010002

References

  [1] 陆爱民，赵艳，刘宝宝. 血清β2-MG、miR-133a联合检测对扩张型心肌病患者预后的评估价值[J]. 岭南心血管病杂志，2020，26(6)：685-688.
     [2] 王岩，陈磊. 扩张型心肌病患者的DC、AC、HRV检测及其与心功能的相关性[J]. 海南医学，2022，33(12)：1505-1507.
     [3] 陈火梅，赖玉琼，莫展，等. 超声心动图评估主动脉瓣置换术后病人心功能及中远期预后的临床价值[J]. 中西医结合心脑血管病杂志，2023，21(5)：895-899.
     [4] 范彩逢，王振华，张守彦，等. 重症心力衰竭患者血清Adropin和炎性趋化因子水平变化及其与左心室重构和预后的关系[J]. 热带医学杂志，2020，20(4)：530-533.
     [5] 中华医学会心血管病学分会，中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志，2018，34(5)：421-434.
     [6] 廖玉华. 中国扩张型心肌病诊断和治疗指南：创新与转化[J]. 临床心血管病杂志，2018，34(5)：435-436.
     [7] 陈志强，杨关林. 中西医结合内科学[M]. 3版. 北京：中国中医药出版社，2016：133-134.
     [8] 黄磊磊，幸红燕，周果. 扩张型心肌病慢性心力衰竭患者血清POSTN、STAT3水平变化及其临床意义[J]. 山东医药，2023，63(31)：28-32.
     [9] 叶丽虹，余小君，吴轲，等. 超声心动图参数联合血清NT-pro BNP、suPAR、PTX-3预测慢性心力衰竭患者预后的临床研究[J]. 现代生物医学进展，2023，23(18)：3479-3483.
     [10] 苏洁，王书伟，马维东，等. 超声心动图参数联合血清Adropin、SDC4对急性STEMI患者早期静脉溶栓预后的预测价值[J]. 中国急救复苏与灾害医学杂志，2024，19(8)：993-996.
     [11] 徐艳，余敏，王璐璐. 改良早期预警评分联合超声心动图及血清标志物预测老年慢性心力衰竭病人长期预后的临床价值[J]. 中西医结合心脑血管病杂志，2022，20(24)：4572-4576.
     [12] 吕佳仁，江惠琼，许德星. 超声心动图参数联合心电图T波振幅评估扩张型心肌病患者左室收缩功能的临床价值[J]. 临床超声医学杂志，2023，25(12)：990-995.
     [13] Berezina TA，Berezin OO，Novikov EV，et al. Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide[J]. Biomolecules，2024，14(12)：1615-1625.
     [14] 赵颖超，额尔敦其木格，戴军有，等. 急性心力衰竭患者血清Adropin、sST2、Gal-3水平与预后的关系分析[J]. 现代生物医学进展，2020，20(7)：1326-1330.
     [15] 廖贵娟，陶伟. 冠心病合并心力衰竭患者血清Adropin、sST2、BNP水平与预后的关系分析[J]. 标记免疫分析与临床，2020，27(12)：2112-2116.
     [16] 梁善福，孙运，张申伟，等. 急性失代偿心力衰竭病人出院时sST2、Adropin、RDW水平与6个月内不良事件发生的关系[J]. 中西医结合心脑血管病杂志，2022，20(22)：4181-4184.
     [17] 宋势波，欧阳斯华，李艺玲. 超声心动图联合血清β2-微球蛋白、同型半胱氨酸评估扩张型心肌病患者心力衰竭风险的价值[J]. 临床超声医学杂志，2022，24(6)：465-468.
     [18] 周秀，李毓娟，赵小瑞. 冠心病不稳定型心绞痛病人血清ENS、adropin表达及其与预后的关系[J]. 中西医结合心脑血管病杂志，2022，20(10)：1823-1826.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]